Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)(LOTIS-9) | terminated | Phase 2 | 41 | ADC Therapeutics S.A.INDUSTRY | 4 | Jan 30, 2025 | clinicaltrials |
| NCT06781450 | Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context(PRIMICI) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| 1 |
| Jan 30, 2025 |
| clinicaltrials |
| NCT04432506 | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06796517 | Immunotherapy in Lymphoma | recruiting | — | 72 | Sung-Soo ParkOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05529524 | Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) | completed | — | 6 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | completed | Phase 3 | 256 | Denovo Biopharma LLCINDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT04890236 | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | completed | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782789 | An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program(TALOs) | recruiting | — | 96 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782854 | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy | completed | — | 102 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04716075 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)(ACALLO) | completed | Phase 2 | 29 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777290 | Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma | completed | — | 14 | Charles University, Czech RepublicOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | terminated | Phase 2 | 55 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760936 | Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients(PIXBRIDGE) | active not recruiting | — | 15 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06757894 | Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06755775 | PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma | recruiting | — | 150 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | terminated | Phase 2 | 169 | MEI Pharma, Inc.INDUSTRY | 14 | Dec 31, 2024 | clinicaltrials |
| NCT06701357 | CR-CHOP+X in Previously Untreated DEL | recruiting | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | recruiting | Phase 3 | 476 | InnoCare Pharma Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06748521 | Dynamic CtDNA-guided Targeted Therapy in DLBCL | not yet recruiting | Phase 2 | 108 | Ruijin HospitalOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06750991 | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) | not yet recruiting | Phase 2 | 34 | Ruijin HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Acerta Pharma BVINDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05172700 | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | approved for marketing | — | — | Loxo Oncology, Inc.INDUSTRY | 0 | Dec 18, 2024 | clinicaltrials |
| NCT06734624 | The Microbiome in Blood Cancer and HLH | not yet recruiting | — | 750 | University of NottinghamOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2(ImbruVeRCHOP) | completed | Phase 1 / Phase 2 | 38 | Prof. Dr. Clemens SchmittOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03410901 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | completed | Phase 1 | 14 | Ronald LevyOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05233033 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | completed | Phase 1 | 7 | Kymera Therapeutics, Inc.INDUSTRY | 2 | Dec 10, 2024 | clinicaltrials |
| NCT06608147 | MOLyF : Bone Marrow and Follicular Lymphoma(MOLyF) | recruiting | N/A | 200 | Rennes University HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04726787 | RadiothErapy priMIng for CAR-T(REMIT) | active not recruiting | N/A | 6 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06534463 | Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)(MOTIVE) | recruiting | — | 500 | Ruijin HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06704555 | Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | terminated | Phase 2 | 5 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | active not recruiting | Phase 1 / Phase 2 | 23 | Joshua BrodyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT05910801 | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma(V-MIND) | recruiting | Phase 2 | 100 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06674096 | RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL | recruiting | Phase 2 | 44 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02268851 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | completed | Phase 1 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03630042 | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia(PembroWM) | completed | Phase 2 | 17 | University College, LondonOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | terminated | Phase 3 | 82 | MEI Pharma, Inc.INDUSTRY | 19 | Nov 4, 2024 | clinicaltrials |
| NCT06669143 | Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT03053440 | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)(ASPEN) | completed | Phase 3 | 201 | BeiGeneINDUSTRY | 12 | Oct 26, 2024 | clinicaltrials |
| NCT03145064 | Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma | completed | Phase 2 | 41 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03206970 | Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 2 | 86 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03332173 | Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) | completed | Phase 2 | 44 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03520920 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | completed | Phase 2 | 41 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03846427 | Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma(MAGNOLIA) | completed | Phase 2 | 68 | BeiGeneINDUSTRY | 9 | Oct 26, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jan 30, 2025source: clinicaltrials